In their recent large pooled analysis of outcomes in patients with early-stage HER2-positive BC, Zavardas and colleagues reported an overall PIK3CA mutation rate of 22% [11], similar to the 21% mutation rate we report. The gene discussed is PIK3CA; the disease is breast cancer.